Oklahoma legislation · 2026 Regular Session
Oklahoma HB3834: Ibogaine clinical trials; Oklahoma Breakthrough Therapy Act; terms; requirements for drug developers; contractual terms; intellectual property rights; reports; intellectual property account; effective date.
Status: Signed into law, May 12, 2026
What the bill says
An Act relating to ibogaine clinical trials; creating the Oklahoma Breakthrough Therapy Act; providing short title; defining terms; directing the State Department of Health to enter into certain contracts subject to specified conditions; establishing requirements for drug developers; providing contractual terms; providing for intellectual property rights; requiring submission of certain reports; creating the Ibogaine Development Revolving Fund; specifying type of fund and sources of monies; providing for budgeting and expenditure of monies for specified purpose…
From the enrolled text, May 6, 2026:
An Act relating to ibogaine clinical trials; creating the Oklahoma Breakthrough Therapy Act; providing short title; defining terms; directing the State Department of Health to enter into certain contracts subject to specified conditions; establishing requirements for drug developers; providing contractual terms; providing for intellectual property rights; requiring submission of certain reports; creating the Ibogaine Development Revolving Fund; specifying type of fund and sources of monies; providing for budgeting and expenditure of monies for specified purpose; granting certain professional immunity to medical professionals; providing for codification; and providing an effective date. SUBJECT: Ibogaine clinical trials SECTION 1. NEW LAW A new section of law to be codified in the Oklahoma Statutes as Section 2-806.1 of Title 63, unless there is created a duplication in numbering, reads as follows: This act shall be known and may be cited as the "Oklahoma Breakthrough Therapy Act". SECTION 2. NEW LAW A new section of law to be codified in the Oklahoma Statutes as Section 2-806.2 of Title 63, unless there is created a duplication in numbering, reads as follows: As used in this 2. "Drug developer" means a public-private partnership, forprofit, nonprofit, or public benefits corporation engaged in drug development and manufacturing that has established an ibogaine drug development agreement with at least one additional state with a plan to conduct drug development clinical …